2026 Agenda

Moderators: Carel le Roux, MD, PhD & Ildiko Lingvay, MD

1. 8:30am–8:45amOpening Remarks of the SOLAR ConferenceMazen Noureddin, MD, MHSc
2. 8:45am–9:05amState of the Art Lecture: The Evolving Understanding of the Disease of Obesity that is Impacting Clinical TrialsCarel le Roux MD, PhD
3. 9:05am–9:25amWhat did we learn with the STEP and SELECT trials with Semaglutide that changed how we want to do clinical trials now?Domenica Rubino, MD
4. 9:25am–9:35amBreak
5. 9:35am–9:55amWhat did we learn with the SURMOUNT trials with Tirzepatide that changed how we do clinical trials now?Layla Abushamat, MD
6. 9:55am–10:15amWhat did we learn with the new phase 2 and 3 trials with Multihormone Agonists that changed how we want to do clinical trials now?Ildiko Lingvay, MD
7. 10:15am–10:25amCDs Abstract of Choice - Efficacy and safety of survodutide for the treatment of obesity in adults without diabetes: primary results from the SYNCHRONIZE®-1 phase 3 trialCarel le Roux, MD, PhD
8. 10:25am–10:35amCDs Abstract of Choice - Effect of Enicepatide (CT-388) on Liver Fat in Adults With Obesity, With or Without Type 2 DiabetesAlexandra Steinberg, MD, PhD
9. 10:35am–10:55amPanel discussionDomenica Rubino, Dimple Desai, Julia Dunn, Layla Abushamat, Isabel Kloer
10. 10:55am–11:00amLunch Pickup Break (Please Return Promptly)
11. 11:00am–12:00pmProduct theaterIpsen Pharmaceuticals Product Theater (Lunch) - Cholestatic Liver Diseases: Discover a Treatment Option in PBC & Learn More About PFICNaim Alkhouri, MD, FAASLD, ABOM

Moderators: Raj Vuppalanchi, MD & Lily Dara, MD

1. 12:00pm–12:20pmPBC Update: Current Status and Future DirectionsRaj Vuppalanchi, MD
2. 12:20pm–12:40pmAutoimmune Hepatitis: An Unmet Need—Promises, Pitfalls, and the Path ForwardLily Dara, MD
3. 12:40pm–1:00pmGenetic Liver Diseases 1: What's New in A1AT Deficiency, Wilson Disease, and HemochromatosisKris Kowdley, MD
4. 1:00pm–1:20pmGenetic Liver Disease 2: Genetic Cholestasis from PFIC to Alagille Syndrome to BASDWing-Kin Syn, MD
5. 1:20pm–1:40pmPanel DiscussionPanel: Kris Kowdley, Wing-Kin Syn, Raj Vuppalanchi, Lily Dara
6. 1:40pm–2:00pmBreak

7. Moderators: Norah Terrault, MD, MPH & Nancy Reau, MD

8. 2:00pm–2:20pmPractice Guidelines and Trials Challenges for Chronic HBV and HDV: Are We Moving the Needle?Theo Heller, MD
9. 2:20pm–2:40pmUpdate on Clinical Trials of Novel Agents Targeting Functional Cure for HBVNorah Terrault, MD, MPH
10. 2:40pm–3:00pmCHB Treatment and HCV Elimination in 2030: Can we Predict the Future?Nancy Reau, MD
11. 3:00pm–3:20pmPanel DiscussionPanel: Theo Heller, Nancy Reau, Norah Terrault
12. 3:20pm–6:00pmMeetings, Poster Viewing, and Self-Directed Learning
13. 6:00pm–8:00pmReception

Moderators: Naim Alkhouri, MD & Manu Chakravarthy, MD, PhD

1. 9:00am–9:20amSteatotic Liver Disease in 2026Mazen Noureddin, MD, MHSc
2. 9:20am–9:40amResmetirom and Semaglutide are now FDA Approved: What Should Clinicians Do Today?Naim Alkhouri, MD
3. 9:40am–10:00amCurrent Update on Phase 3 TrialsAlina Allen, MD
4. 10:00am–10:20amPanel DiscussionMazen Noureddin, Alina Allen, Henry Chang
5. 10:20am–10:35amBreak
6. 10:35am–10:50amRNA Interference and Genetic TherapiesNaga Chalasani, MD
7. 10:50am–11:10amPROs in MASH Trials, Which One and How to ImplementZobair Younossi, MD
8. 11:10am–11:20amCDs Abstract of Choice – The Disease Severity Index (DSI) from the Oral Cholate Challenge Test (HepQuant DuO®) Defines Varices Risk Across Child-Pugh A5 and A6 and MASH Versus Non-MASH EtiologiesJoanne C. Imperial, MD, FAASLD
9. 11:20am–11:30amCDs Abstract of Choice – Miricorilant, a Selective Glucocorticoid Receptor Modulator, Reprograms Hepatic Gene Networks in Metabolic Dysfunction–Associated SteatohepatitisRafael Mayoral Monibas, PhD
10. 11:30am–11:50amPanel DiscussionPanel: Becky Taub, Zobair Younossi, Mazen Noureddin, Meena Bansal, Naga Chalasani, Scot Roberts
11. 11:50am–12:00pmLunch Pickup Break (Please Return Promptly)
12. 12:00pm–1:00pmProduct theaterMadrigal Pharmaceuticals Product Theater (Lunch) - Rezdiffra: Unlocking the Potential of a Liver-Directed TreatmentRashmee Patil, MD & Kris Kowdley, MD, FAASLD

Moderators: Mazen Noureddin, MD & Stuart Kendrick, MD, PhD

1. 1:00pm–1:20pmNITs: The Reasonably Likely to Predict Outcomes and the path to full ValidationJörn Schattenberg, MD
2. 1:20pm–1:40pmUpdate on the Role of liver biopsy in MASH trials: When do I use it?Cynthia Behling, MD
3. 1:40pm–2:00pmDesigning Non-Cirrhotic MASH Trials without Liver Biopsy: Pros & ConsVlad Ratziu, MD
4. 2:00pm–2:20pmDesigning Cirrhosis TrialsArun Sanyal, MD
5. 2:20pm–2:50pmUpdates on Promising NITs (ProC3, cT1, MASEF score)Manu Chakravarthy, MD, Carlos Duncker, MD, PhD & Frank Amato
6. 2:50pm–3:05pmPanel DiscussionPanel: Jörn Schattenberg, Cynthia Behling, Bilal Hameed, Arun Sanyal, Vlad Ratziu
7. 3:05pm–6:00pmMeetings, Poster Viewing, and Self-Directed Learning

Moderators: Ramy Younes, MD, PhD & Meena Bansal, MD

1. 8:30am–8:50amOvercoming MASH Trials Difficulties, Liver Biopsy, Biomarkers and RetentionRashmee Patil, MD
2. 8:50am–9:10amUse of GLP-1 and their Effect in MASH Trials: How to control and mitigate during trialsMeena Bansal, MD
3. 9:10am–9:30amWhat is a Stellar MASH Site: The Sponsor's Wish ListMichelle Long, MD
4. 9:30am–9:50amPanel DiscussionPanel: Rashmee Patil, Michelle Long, Michael Betel, Lars Hansen, Joseph Galati
5. 9:50am–10:10amBreak

Sharks: Mazen Noureddin, Naim Alkhouri, Bill Sibold, Stuart Kendrick, Michelle Long, Manu Chakravarthy

1. 10:10am–10:20amPitchKriya
2. 10:20am–10:30amSharks
3. 10:30am–10:40amPitchHepanova
4. 10:40am–10:50amSharks
5. 10:50am–11:00amLunch Pickup Break (Please Return Promptly)
6. 11:00am–12:00pmProduct theaterBoehringer Ingelheim Pharmaceuticals Product Theater (Lunch) - Obesity and its Interplay in Metabolic DysfunctionDonna H. Ryan, MD, Jacqueline Stephens, PhD & Fernando Bril, MD

Moderators: Mazen Noureddin, MD & Brian Lee, MD

1. 12:05pm–12:25pmCurrent Update on Clinical Trials for MetALD and ALDNaim Alkhouri, MD
2. 12:25pm–12:45pmMetALD and ALD Phase 2 Trials DesignBrian Lee, MD
3. 12:45pm–1:05pmMetALD and ALD Phase 3 Trials DesignMazen Noureddin, MD
4. 1:05pm–1:25pmPanel DiscussionNaim Alkhouri, Brian Lee, Mazen Noureddin, David Victor, Scot Roberts, Norah Terrault

Moderators: Ashwani Singal, MD & Lisa Boyette, MD, PhD

1. 1:25pm–1:45pmHow to Deal with Active Alcohol Intake during the TrialsJessica Mellinger, MD
2. 1:45pm–2:05pmNIT in MetALD/ALD: The Reasonably Likely to Predict OutcomesAshwani Singal, MD
3. 2:05pm–2:25pmSites Challenges in MetALD and ALD trials (Sites vs Sponsors Perspective (10 min each)Nikhil Vergis, MD (Sponsor) & Bilal Hameed, MD (Site)
4. 2:25pm–2:35pmCDs Abstract of Choice – Changes in Liver Fibrosis Following 24 Weeks of Pemvidutide Treatment in Patients with Metabolic Dysfunction-Associated Steatohepatitis: Quantitative Digital Pathology Analysis from the IMPACT Phase 2b Multicenter Randomized Placebo-Controlled TrialShaheen Tomah, MD
5. 2:35pm–2:55pmPanel DiscussionPanel: Ramy Younes, Nikhil Vergis, Manu Chakravarthy, Jessica Mellinger, Bilal Hameed
6. 2:55pm–3:10pmBreak

Sharks: Mazen Noureddin, Naim Alkhouri, Nikhil Vergis, Brian Lee, Ramy Younes, David Soergel

1. 3:10pm–3:20pmPitchHistoIndexYukti Choudhury, MD
2. 3:20pm–3:30pmSharks
3. 3:30pm–3:40pmPitchNeuraly
4. 3:40pm–3:50pmSharks
5. 3:50pm–4:00pmPitchClosing RemarksMazen Noureddin, MD & Naim Alkhouri, MD
6. 4:00pm–6:00pmMeetings, Poster Viewing, and Self-Directed Learning